Clinical efficacy and safety of programmed death 1 inhibitors combined with anlotinib as the second-line therapy in treating patients with advanced esophageal squamous cell carcinoma

SUN Wei; DAI Hong

doi:10.7619/jcmp.20231808

Journal of Clinical Medicine in Practice > 2023 > 27(19): 17-21. > DOI: 10.7619/jcmp.20231808

SUN Wei, DAI Hong. Clinical efficacy and safety of programmed death 1 inhibitors combined with anlotinib as the second-line therapy in treating patients with advanced esophageal squamous cell carcinoma[J]. Journal of Clinical Medicine in Practice, 2023, 27(19): 17-21. DOI: 10.7619/jcmp.20231808

Citation:

PDF (936 KB)

Clinical efficacy and safety of programmed death 1 inhibitors combined with anlotinib as the second-line therapy in treating patients with advanced esophageal squamous cell carcinoma

SUN Wei,
DAI Hong

Department of Oncology, the Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangsu, 210029

More Information

Received Date: June 04, 2023
Revised Date: July 23, 2023
Available Online: October 18, 2023

Graphical Abstract

Abstract

Abstract

Objective
To analyze the clinical efficacy and safety of programmed death 1 (PD-1) inhibitors combined with anlotinib as the second-line therapy in treating patients with advanced esophageal squamous cell carcinoma.
Methods
A total of 68 patients with advanced esophageal squamous cell carcinoma diagnosed by histopathology from January 2021 to June 2022 were selected, and they were treated with PD-1 inhibitors plus arotinib targeted therapy after failure of first-line platinum containing chemotherapy regimen, including 32 cases with camrelizumab, 20 cases with sintilimab, and 16 cases with treprinumab immunotherapy. The clinical efficacy and safety of three groups were analyzed.
Results
After efficacy evaluation for 68 patients, there were 18 cases of partial remission, 40 cases of stable disease, and 10 cases of disease progression. The objective response rate and disease control rate were 26.5% and 85.3% respectively, the median progression free survival was 7.5 months (95%CI, 6.6 to 8.4), and the median overall survival was not achieved. In terms of safety, the most adverse reactions were at grade 1 and 2, the incidence of adverse reactions at grade 3 was 14.7%, and adverse reactions at grade 4 and 5 were not observed; all the adverse reactions alleviated after performing targeted treatment.
Conclusion
Patients with advanced esophageal squamous cell carcinoma can significantly benefit from the combination of PD-1 inhibitors and anlotinib as the second-line therapy, and the adverse reactions are controllable.
- advanced esophageal squamous cell carcinoma,
- programmed death 1,
- inhibitors,
- anlotinib,
- the second-line therapy,
- safety

FullText(HTML)

References (18)

References

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[2]	SUN J M, SHEN L, SHAH M A, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study[J]. Lancet, 2021, 398(10302): 759-771. doi: 10.1016/S0140-6736(21)01234-4
[3]	DOKI Y, AJANI J A, KATO K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma[J]. N Engl J Med, 2022, 386(5): 449-462. doi: 10.1056/NEJMoa2111380
[4]	LUO H Y, LU J, BAI Y X, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial[J]. JAMA, 2021, 326(10): 916-925. doi: 10.1001/jama.2021.12836
[5]	WANG Z X, CUI C X, YAO J, et al. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial[J]. Cancer Cell, 2022, 40(3): 277-288, e3. doi: 10.1016/j.ccell.2022.02.007
[6]	LU Z H, WANG J Y, SHU Y Q, et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial[J]. BMJ, 2022, 377: e068714.
[7]	CHAMBERS A, KUNDRANDA M, RAO S, et al. Anti-angiogenesis revisited: combination with immunotherapy in solid tumors[J]. Curr Oncol Rep, 2021, 23(9): 100. doi: 10.1007/s11912-021-01099-7
[8]	MENG X R, WU T, HONG Y G, et al. Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2022, 7(3): 245-253. doi: 10.1016/S2468-1253(21)00378-2
[9]	XU Q, CHEN C B, SUN Y, et al. A phase Ⅱ study of sintilimab plus anlotinib for Chinese patients (pts) with persistent, recurrent or metastatic cervical cancer (CC)[J]. Gynecol Oncol, 2021, 162: S78.
[10]	JIN S L, ZHAO R H, ZHOU C, et al. Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: an open-label, single-arm, phase Ⅱ clinical trial[J]. Int J Cancer, 2023, 152(8): 1648-1658. doi: 10.1002/ijc.34372
[11]	刘良忠, 李小红, 张军, 等. 安罗替尼后线治疗抗PD-1免疫治疗失败的晚期食管鳞癌的临床疗效观察[J]. 重庆医学, 2022, 51(2): 276-280. https://www.cnki.com.cn/Article/CJFDTOTAL-CQYX202202021.htm
[12]	HUANG J, XIAO J X, FANG W T, et al. Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: a double-blind randomized phase 2 trial[J]. Cancer Med, 2021, 10(5): 1681-1689. doi: 10.1002/cam4.3771
[13]	孙魏, 邹玺, 张微, 等. 安罗替尼联合替吉奥二线治疗复发转移性食管鳞癌的临床疗效[J]. 南方医科大学学报, 2021, 41(2): 250-255. https://www.cnki.com.cn/Article/CJFDTOTAL-DYJD202102014.htm
[14]	HUANG J, XU J M, CHEN Y, et al. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study[J]. Lancet Oncol, 2020, 21(6): 832-842. doi: 10.1016/S1470-2045(20)30110-8
[15]	VAN CUTSEM E, KATO K, AJANI J, et al. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life (HRQoL)[J]. Journal of Clinical Oncology, 2021, 39(15_suppl): 4012-4012 doi: 10.1200/JCO.2021.39.15_suppl.4012
[16]	KOJIMA T, SHAH M A, MURO K, et al. Randomized phase Ⅲ KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer[J]. J Clin Oncol, 2020, 38(35): 4138-4148. doi: 10.1200/JCO.20.01888
[17]	OKADA M, KATO K, CHO B C, et al. Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3)[J]. Clin Cancer Res, 2022, 28(15): 3277-3286. doi: 10.1158/1078-0432.CCR-21-0985
[18]	葛青青, 石变, 高启龙, 等. PD-1抑制剂联合安罗替尼治疗化疗后进展的晚期食管鳞状细胞癌的回顾性研究[J]. 中国肿瘤临床, 2022, 49(10): 519-523. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL202210008.htm

Cited By

Cited by

Periodical cited type(10)

1.	吴静，张颖，肖文焕. 团体心理剧疗法对围绝经期精神分裂症患者抑郁、自尊及应对能力的影响. 实用临床医药杂志. 2025(01): 125-129+143 . 本站查看
2.	张颖，葛丽娜，曹雷，邹杰，周磊. 正念训练对慢性失眠障碍患者治疗效果及炎症因子的影响. 武警医学. 2024(01): 30-33 .
3.	梁娜，郭雪丽，赵福涛. 基于IMB模型的睡眠心理行为护理在慢性失眠患者中的应用. 海南医学. 2024(10): 1489-1493 .
4.	史亮亮，陈丽梅，陈丽. 柴胡温经汤加减治疗围绝经期肝郁阴虚夹瘀型顽固失眠症临床观察. 湖北中医药大学学报. 2024(03): 76-78 .
5.	刘艳霞，单锋波. 正念减压疗法联合艾司唑仑片对更年期失眠患者睡眠质量及负面情绪的影响. 心理月刊. 2024(11): 137-139 .
6.	王雅娟，杨洁. 分析步行运动联合正念干预对卵巢癌患者睡眠质量的影响. 世界睡眠医学杂志. 2024(05): 1102-1105 .
7.	黄小丽，农秀明. 中医外治法治疗失眠临床研究进展. 广西中医药大学学报. 2024(04): 70-73 .
8.	何兰英，何风英，李平，赵栋，孙岩. 基于正念的失眠认知疗法对老年非器质性失眠症患者正念、多导睡眠参数的影响. 临床误诊误治. 2024(12): 74-78 .
9.	潘晨璐，孟萍. 脐灸联合穴位敷贴在围绝经期失眠患者中的应用效果. 中国当代医药. 2024(25): 79-82 .
10.	李晶晶，宋玉娇，王婷，于洁，周敬，蒋桂军，李艳青. 睡眠健康教育联合自助式正念减压训练对围绝经期失眠患者的影响. 齐鲁护理杂志. 2024(21): 6-10 .

Other cited types(3)

Get Citation

PDF

XML

Article views (130) PDF downloads (14) Cited by(13)

Turn off MathJax

Article Contents

Abstract

References

Clinical efficacy and safety of programmed death 1 inhibitors combined with anlotinib as the second-line therapy in treating patients with advanced esophageal squamous cell carcinoma

Abstract

References

Cited by

Periodical cited type(10)

Other cited types(3)

Catalog

Export File

Citation

Format

Content